Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Short Interest Update

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 93,300 shares, an increase of 311.0% from the April 30th total of 22,700 shares. Based on an average daily volume of 57,700 shares, the short-interest ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Can-Fite BioPharma in a research note on Monday, March 13th. StockNews.com assumed coverage on shares of Can-Fite BioPharma in a report on Thursday. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Virtu Financial LLC bought a new position in shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 56,322 shares of the biotechnology company’s stock, valued at approximately $52,000. Virtu Financial LLC owned about 0.21% of Can-Fite BioPharma at the end of the most recent quarter. Hedge funds and other institutional investors own 1.82% of the company’s stock.

Can-Fite BioPharma Price Performance

Shares of Can-Fite BioPharma stock traded down $0.09 during trading on Friday, hitting $2.24. 14,312 shares of the company’s stock traded hands, compared to its average volume of 75,001. The company has a market cap of $7.93 million, a PE ratio of -0.63 and a beta of 1.29. Can-Fite BioPharma has a twelve month low of $1.52 and a twelve month high of $11.20. The firm’s fifty day moving average price is $2.38 and its 200 day moving average price is $2.09.

Can-Fite BioPharma (NYSEAMERICAN:CANF – Get Rating) last released its quarterly earnings results on Thursday, March 30th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.54). The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.50 million. Can-Fite BioPharma had a negative net margin of 1,255.93% and a negative return on equity of 120.33%. As a group, equities research analysts anticipate that Can-Fite BioPharma will post -2.03 earnings per share for the current year.

Can-Fite BioPharma Company Profile

(Get Rating)

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.